- Home
- CODA vs XFOR Comparison
CODA vs XFOR Comparison
Compare CODA & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CODA
- XFOR
- Stock Information
- Founded
- CODA 1994
- XFOR 2014
- Country
- CODA United States
- XFOR United States
- Employees
- CODA N/A
- XFOR N/A
- Industry
- CODA Industrial Machinery/Components
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CODA Industrials
- XFOR Health Care
- Exchange
- CODA Nasdaq
- XFOR Nasdaq
- Market Cap
- CODA 88.8M
- XFOR 84.3M
- IPO Year
- CODA N/A
- XFOR N/A
- Fundamental
- Price
- CODA $8.76
- XFOR $3.26
- Analyst Decision
- CODA Strong Buy
- XFOR Strong Buy
- Analyst Count
- CODA 1
- XFOR 3
- Target Price
- CODA $11.00
- XFOR $34.17
- AVG Volume (30 Days)
- CODA 66.2K
- XFOR 1.6M
- Earning Date
- CODA 09-15-2025
- XFOR 11-12-2025
- Dividend Yield
- CODA N/A
- XFOR N/A
- EPS Growth
- CODA 21.86
- XFOR N/A
- EPS
- CODA 0.30
- XFOR N/A
- Revenue
- CODA $22,758,966.00
- XFOR $32,774,000.00
- Revenue This Year
- CODA $30.82
- XFOR $1,313.84
- Revenue Next Year
- CODA $20.84
- XFOR N/A
- P/E Ratio
- CODA $29.09
- XFOR N/A
- Revenue Growth
- CODA 24.78
- XFOR 5721.31
- 52 Week Low
- CODA $5.76
- XFOR $1.35
- 52 Week High
- CODA $9.89
- XFOR $26.83
- Technical
- Relative Strength Index (RSI)
- CODA 66.55
- XFOR 52.11
- Support Level
- CODA $7.61
- XFOR $3.08
- Resistance Level
- CODA $8.12
- XFOR $3.79
- Average True Range (ATR)
- CODA 0.40
- XFOR 0.48
- MACD
- CODA 0.05
- XFOR -0.10
- Stochastic Oscillator
- CODA 96.43
- XFOR 13.07
About CODA Coda Octopus Group Inc. Common stock
Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company's operations are organized into two reportable segments: the Products Segment (Marine Technology Business serving the subsea market and PAL, which sells other products (acoustic hydrophones and acoustic materials to a different market); and the Services Segment (Marine Engineering Business). Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.